Yes, SCLN is doing excellent. I suppose that it is a combination of factors that is helping its price rebound. First, SCLN was overly depressed due to tax loss selling. Now that is over, so things are getting back to normal (more or less). That could be described as the January effect, which tends to help beaten down small cap stocks. In addition, there is some definite "buy on the rumour" going on about the pending phase 3 trial and possible U.S. partnership for Zadaxin. It's nice to see SCLN get some ground back.
As far as ILXO goes, the MMs are really playing with people's minds lately. They are moving the price around wildly without even a hint of volume. I suspect that more than a few are trying to collect some additional shares prior to the FDA approval of Campath which could come at any time. Once Campath is approved, it will be interesting to see what the MMs do.
At any rate, most of the biotech sector took a boot in the head today (BTK is down almost 7%), so I won't complain about either ILXO or SCLN (at least for the remainder of the day).